RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different

A recent phase I clinical study tested anti-ROR1 chimeric antigen receptor (CAR) T cells in patients with chronic lymphocytic leukemia, non-small cell lung cancer, and triple-negative breast cancer. The product could be safely administered and had activity in chronic lymphocytic leukemia but less so in non-small cell lung cancer and triple-negative breast cancer. See related article by Jaeger-Ruckstuhl et al., p. 503.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2024-12-03
DOI
https://doi.org/10.1158/1078-0432.ccr-24-3688
Citations
2
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.57

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different

Sebastian Kobold
2 citations
Clinical Cancer Research
CAR-T cell therapy research
0.57
article

RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different

Sebastian Kobold
article en
2 citations

Abstract

A recent phase I clinical study tested anti-ROR1 chimeric antigen receptor (CAR) T cells in patients with chronic lymphocytic leukemia, non-small cell lung cancer, and triple-negative breast cancer. The product could be safely administered and had activity in chronic lymphocytic leukemia but less so in non-small cell lung cancer and triple-negative breast cancer. See related article by Jaeger-Ruckstuhl et al., p. 503.

Clinical Cancer ResearchVol. 31(3)
German Cancer Research Center (DE), Heidelberg University (DE), Helmholtz Zentrum München (DE), LMU Klinikum (DE), Ludwig-Maximilians-Universität München (DE)
Melanoma Research Alliance, European Commission, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Bayerische Forschungsstiftung, Else Kröner-Fresenius-Stiftung, José Carreras Leukämie-Stiftung, Ludwig-Maximilians-Universität München, Deutsche Krebshilfe, Hector Stiftung, Elitenetzwerk Bayern
Good health and well-being
Openalex Percentile: Top 26%
CAR-T cell therapy research
0.57
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different — Sebastian Kobold · Clinical Cancer Research (2024) | TGRS Research Map | TGRS